Table 2.
Effects of risk factors on brain metastasis by univariate and multivariate Cox analysis.
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Variables (Risk Factors) | n (%) | HR (95%CI) | p Value | HR (95%CI) | p Value |
| GCSF use | 63 (52.1) | 2.538 (1.127–5.716) | 0.025 * | 2.479(1.023–6.007) | 0.044 * |
| Menopause Status | 89 (73.6) | 4.062 (1.968–8.384) | 0.000 * | 3.305 (1.521–7.179) | 0.003 * |
| Hormone treatment | 79 (65.3) | 2.713 (1.261–5.836) | 0.011 * | 2.266 (1.025–5.011) | 0.043 * |
| Hormone receptor status | 78 (64.5) | 1.557 (0.738–3.285) | 0.245 | -- | |
| HER2 treatment | 34 (28.1) | 2.800(1.331–5.889) | 0.007 * | 2.159 (1.013–4.603) | 0.046 * |
| HER2 Status | 55 (45.5) | 1.138 (0.543–2.384) | 0.731 | -- | -- |
| TNBC | 15 (12.4) | 0.381 (0.142–1.018) | 0.054 * | --- | --- |
| Target therapy | 26 (21.5) | 0.600 (0.254–1.414) | 0.243 | -- | --- |
| Myelosuppression | 37 (30.6) | 1.392 (0.596–3.251) | 0.445 | --- | --- |
| Neutropenia | 46 (38.0) | 3.276 (1.530–7.013) | 0.002 * | 2.418 (1.054–5.548) | 0.037 * |
| Dosage, cumulated (μg) | |||||
| 0 | 58 (47.9) | 1 | 1 | -- | -- |
| ≤4500 | 30 (24.8) | 1.896(1.223–2.940) | 0.004 * | 1.296 (0.449–3.743) | 0.632 |
| >4500 | 33 (27.3) | 1.255(0.817–1.929) | 0.299 | ---- | --- |
| Dosage density (μg/day) | |||||
| 0 | 58 (47.9) | 1 | 1 | -- | --- |
| <300 | 40 (33.1) | 1.353(0.868–2.107) | 0.182 | --- | --- |
| ≥300 | 24 (19.8) | 1.753(1.142–2.691) | 0.010 * | 1.866 (1.212–2.872) | 0.005 * |
| No. of Chemotherapy | |||||
| <2 | 58(47.9) | 0.664 (0.315–1.398) | 0.281 | --- | ---- |
| ≥2 | 63 (52.1) | 0.890 (0.431–1.842) | 0.754 | --- | --- |
Remarks: HR: Hazard ratio; CI: Confidence interval; (μg) microgram which is one millionth of a gram or one thousandth of a milligram; GCSF: granulocyte colony-stimulating factor; n (%): number of risk factors/percentage of total patients = 121). HR+ (estrogen receptor or progesterone receptor positive).* statistical significance.